Entering text into the input field will update the search result below

Atara adds 16% ahead of Phase 2 data for multiple sclerosis candidate

Jul. 12, 2022 2:48 PM ETAtara Biotherapeutics, Inc. (ATRA)By: Dulan Lokuwithana, SA News Editor

Success business chart with green arrow up and USA dollars background. Profit and money. Financial and business graph. Stock market growth 3d illustration.

JuSun/iStock via Getty Images

  • Clinical-stage biotech Atara Biotherapeutics (NASDAQ:ATRA) surged ~16% as the company plans to report interim data on Tuesday from its Phase 2 EMBOLD study for ATA188, a CAR T immunotherapy for progressive multiple sclerosis.
  • About ~1.2M shares have changed hands, exceeding

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About ATRA

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Atara Biotherapeutics, Inc.
Apollomics, Inc.
Adagene Inc.
Pyxis Oncology, Inc.
Calidi Biotherapeutics, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.